Released May 5, 2021, after the close
10-Q filed May 5, 2021, 35 days after period end · 0001558370-21-005903
Q1 2021 · 10-Q
Revenue$81.02M$81.02M +45.3% vs Q1 2020+339.1% vs Q4 2020
Net Income$39.50M$39.50M +85.9% vs Q1 2020N/M vs Q4 2020
EPS Diluted$0.22$0.22 +69.2% vs Q1 2020N/M vs Q4 2020
Operating Income$41,755,000+98.6%
Operating Cash Flow-$19,955,000N/M
Free Cash Flowderived-$20,026,000N/M
Margins · derived
Operating margin51.5%+13.8 pt vs Q1 2020
Net margin48.8%+10.7 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $81.02M | $55.76M | $12.62M | — |
| Net Income | $39.50M | $21.24M | -$17.60M | -$24.39M |
| EPS Diluted | $0.22 | $0.13 | -$0.11 | -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR